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Several microRNAs (miRNAs) are associated with the molecular pathogenesis of hepatocellular carcinoma (HCC).
However, previous studies analyzing the dysregulation of miRNAs in HCC show heterogeneous results. We
hypothesized that part of this heterogeneity might be attributable to variations of miRNA expression deriving from
the HCC capsule or the fibrotic septa within the peritumoral tissue used as controls. Tissue from surgically
resected hepatitis C–associated HCC from six well-matched patients was microdissected using laser
microdissection and pressure catapulting technique. Four distinct histologic compartments were isolated: tumor
parenchyma (TP), fibrous capsule of the tumor (TC), tumor-adjacent liver parenchyma (LP), and cirrhotic septa of
the tumor-adjacent liver (LC). MiRNA expression profiling analysis of 1105 mature miRNAs and precursors was
performed using miRNA microarray. Principal component analysis and consecutive pairwise supervised
comparisons demonstrated distinct patterns of expressed miRNAs not only for TP versus LP (e.g., intratumoral
down-regulation of miR-214, miR-199a, miR-146a, and miR-125a; Pb .05) but also for TC versus LC (including
down-regulation within TC of miR-126, miR-99a/100, miR-26a, and miR-125b; Pb .05). The tumor capsule therefore
demonstrates a tumor-like phenotype with down-regulation of well-known tumor-suppressive miRNAs. Variations
of co-analyzed fibrotic tissue within the tumor or in controls may have profound influence on miRNA expression
analyses in HCC. Several miRNAs, which are proposed to be HCC specific, may indeed be rather associated to the
tumor capsule. As miRNAs evolve to be important biomarkers in liver tumors, the presented data have important
translational implications on diagnostics and treatment in patients with HCC.
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Hepatocellular carcinoma (HCC) is a major complication of end-stage
liver disease. The worldwide annual incidence of HCC is estimated to
be 600,000 [1–4]. In Western countries and Japan, the incidence of
hepatitis C virus (HCV)–related liver cirrhosis and liver cancer is rising
because of the HCV epidemic [5,6]. A further increase is assumed,
because obesity and nonalcoholic steatohepatitis have been identified
as risk factors of HCC especially in Western countries [7].
MicroRNAs (miRNAs) are a class of endogenous small regulatory
RNA molecules that regulate mRNA expression by either transla-
tional repression or mRNA degradation [8]. MiRNAs are involved inA
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Table 1. Patient Cohort Used for Microarray Experiments (Screening Cohort)
Age—mean (min, max) 65 (54–80) (years)
Gender—no. (%)
Female 4 (66)
Male 2 (33)
Ancestry region—no.
Europe 6 (100)
Underlying liver cirrhosis 6 (100)
ISHAK fibrosis score = 6 6 (100)
METAVIR fibrosis score = F4 6 (100)
Cause of liver cirrhosis—no. (%)
HCV 6 (100)
HCV genotype—no. (%)
Genotype 1 5 (83)
Genotype 3 1 (17)
Body mass index—mean ± SD** 31.5 ± 4.2 (kg/m2)
ECOG performance status—no. (%)**
0 5 (83)
1 1 (17)
Child-Pugh class—no. (%)**
A 6 (100)
MELD score—median (min, max)** 9.33 (7, 11)
AFP serum level—median (min, max)** 15 (2.9, 58) ng/ml
BCLC stage—no. (%)**
0 5 (83)
A 1 (17)
Histologic grading (G)—no. (%)*
G1 2 (11)
G2 4 (79)
*Screening microarray experiments were performed for seven patients. One technical outlier sample
was removed from the analysis. **At the time point of HCC resection.
Translational Oncology Vol. 7, No. 6, 2014 miRNAs in HCC Tissue Compartments Peveling-Oberhag et al. 673the regulation of genes associated with different biologic processes,
such as development, cell proliferation, apoptosis, and tumorigenesis
[9]. Various studies have uncovered dysregulation of different
miRNAs in HCC, with implication for prognosis and as possible
targets for future therapy [10–12]. Unfortunately, data published on
miRNA expression in HCC are highly heterogeneous and partly
conflicting. Of note, only a small number of specific miRNAs were
found consistently upregulated or downregulated in different studies
[13]. Part of this heterogeneity of expression data may be attributable
to HCC being a heterogeneous disease. Expression patterns of
miRNAs correlate with activation of different well-known oncogenic
pathways in HCC (e.g., β-catenin, mTOR, or interferon response–
related pathways) [14]. Moreover, some miRNAs correlate with early
stages of liver carcinogenesis, while at later HCC stages a global
miRNA down-regulation has been found [15]. Apart from cancer
cell–specific factors, miRNA expression in HCC is influenced by
non–tumor-associated factors such as differences in ethnicity, etiology
of liver disease, or progression of underlying liver fibrosis [16,17].
Early studies investigating miRNA expression in HCC compared
HCC tissue to healthy liver tissue of different patient cohorts [18].
More recently, tumor-adjacent non-tumorous tissue (TAT) of the
same HCC patient has been preferred as control [19,20]. Throughout
most of the studies, whole tissue sections from either fresh tissue or
formalin-fixed paraffin-embedded (FFPE) tissue have been used.
When HCC whole tissue sections are used, the extracted RNA
originates from all cell types comprising the tumor, among which the
fibrous compartment may contribute a particular source of variation,
especially as the HCC capsule not only surrounds the macroscopic
tumor nodule but often shows a radial distribution throughout the
tumor section. In addition, tissue sections of TAT are a similar mixture
of liver cells and cirrhotic septa. Both capsule tissues consist of fibrous
connective tissue and different cellular components including
fibroblasts, lymphocytes, and granulocytes. We therefore speculated
that quality and quantity of co-analyzed non-tumorous tissue could
contribute to the heterogeneity of miRNA expression data in HCC.
To study the influence of non–tumor-associated factors on HCC
miRNA expression in more detail, we isolated different tissue
compartments of the tumor-infiltrated liver and studied patterns of
miRNAs in their respective microenvironment.
Material and Methods
Patient Selection
The current study is a retrospective analysis, which was approved
by the local Ethics Committee of the University Hospital Frankfurt,
Germany (Ethik-Kommission des Fachbereichs Medizin der Johann
Wolfgang Goethe-Universität). Written informed consent was
obtained from all patients. The screening group of six patients was
carefully selected for matching clinical characteristics to eliminate bias
by ethnicity, tumor stage, liver function, or type of underlying liver
disease. All patients underwent primary surgical resection of HCV-
associated HCC [all Barcelona Clinic Liver Cancer Staging System
(BCLC) stage 0/A; see Table 1]. The validation group consists of 20
patients, all HCV-positive and subject to either primary resection or
liver transplantation (Table 2).Histologic Assessment of Liver Cancer
Diagnosis of HCC was confirmed by an experienced pathologist.
Tumors were classified according to BCLC criteria, and staging andgrading were assessed following current TNM classification of
malignant tumors guidelines [3,21]. All patients featured underlying
liver cirrhosis. Two observers independently evaluated the percentage
of each tissue compartment within the whole tissue sections
(Tables S1 and S2 [48]).
Isolation and Expression Profiling Analysis of miRNA
FFPE tissue from surgically resected HCC was microdissected
using laser microdissection and pressure catapulting technique with a
UV laser beam (PALM). Four distinct histologic compartments were
isolated: tumor parenchyma (TP), fibrinous capsule of the tumor
(TC), tumor-adjacent liver parenchyma (LP), and cirrhotic septa of
the tumor-adjacent liver (LC; Figure S1). Total RNA was extracted
from tumor FFPE specimen using an RNeasy FFPE Kit (Qiagen,
Hilden, Germany) following the manufacturer's protocol. RNA
quantification was performed using a Nanodrop 2000 spectrometer
(Thermo Fisher Scientific, Wilmington, USA) and 50 ng of total
RNA was used for further analysis. We performed a large-scale
miRNA expression profiling analysis of 1105 miRNAs using
Affymetrix GeneChip miRNA Array v2.0 in a total of 28 tissue
compartments. The probe set composition of the arrays is available at
www.affymetrix.com. Microarray experiments were performed fol-
lowing the manufacturer's protocol with exception to the hybridiza-
tion duration. Hybridization time was extended from 18 to 40 hours
to compensate for low amount RNA input, following the
recommendation of the manufacturer. The data discussed in this
publication have been deposited in NCBI's Gene Expression
Omnibus [22] and are accessible through Gene Expression Omnibus
Series accession number GSE54537 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE54537).
Real-Time Polymerase Chain Reaction miRNA Expression Analysis.
TaqManMicroRNAQ-RT-PCR assays (Applied Biosystems,Darmstadt,
Germany) were used to quantifymiRNAs according to themanufacturer’s
Table 2. Patient Cohort Used for Quantitative PCR Experiments (Validation Cohort)
Age—mean (min, max) 58 (42–79) (years)
Gender—no. (%)
Female 5 (33)
Male 15 (66)
Ancestry region—no.
Europe 18 (90)
Asia 1 (5)
Africa 1 (5)
Underlying liver cirrhosis 20 (100)
ISHAK fibrosis score = 6 20 (100)
METAVIR fibrosis score = F4 20 (100)
Cause of liver cirrhosis—no. (%)
HCV 20 (100)
HCV genotype—no. (%)
Genotype 1 11 (55)
Genotype 2 1 (5)
Genotype 3 2 (10)
Unknown 6 (30)
Child-Pugh class—no. (%)
A 16 (80)
B 3 (15)
C 1 (5)
MELD score—median (min, max) 11.6 (6, 29)
AFP serum level—median (min, max) 15 (1.9, 84,798) ng/ml
BCLC stage—no. (%)
0 8 (40)
A 11 (55)
B 1 (5)
Histologic grading (G)—no. (%)
G1 3 (15)
G2 13 (65)
G3 3 (15)
G4 1 (5)
Therapy type—no. (%)
Surgical resection 11 (55)
Liver transplantation 9 (45)
TACE prior to resection or transplantation—no. (%) 12 (60)
At the time point of HCC resection. MELD, Model for End-Stage Liver Disease.
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miR-126, and hsa-miR-150) and one endogenous control (U6). Samples
were analyzed in triplicate, and ΔCt values were calculated using the
endogenous control.
MiRNA In Situ Hybridization. miRNA in situ hybridization
(miRNA-ISH) was carried out as reported elsewhere [23]. Briefly, 11
digoxigenin-labeled locked nucleic acid probes antisense to miR-150
or let-7a (Exiqon, Vedbaek, Denmark) were used for overnight
staining on tissue sections at 61°C. Detection was accomplished with
anti-digoxigenin alkaline phosphatase-conjugated Fab fragment
followed by nitro blue tetrazolium chloride/5-bromo-4-chloro-3-
indolyl phosphate color development (Roche, Basel, Switzerland).
Bioinformatic and Statistical Analyses
Clinical and biochemical characteristics of patients were expressed
as mean ± SD or median and range as appropriate. Unless indicated
otherwise, all tests were two tailed and P values b .05 were considered
significant. Unpaired or paired Student’s t test was applied as
appropriate. Bioinformatic analysis of miRNA profiles was performed
using the statistical computing environment R. Additional software
packages (HTqPCR, geneplotter, and gplots) were taken from the
Bioconductor project. Unsupervised hierarchical clustering was
performed for miRNAs with an SD ≥ 1.5 across all samples using
the Manhattan distance method and the average linkage method. For
the supervised analysis, expression intensity and variance filters were
used to reduce the dimension of the microarray data. Data were
filtered by an intensity filter (gene intensity is N100 in at least 25% ofthe samples, if the group size is equal) as well as a variance filter (the
interquartile range of log2 intensities is N0.5, if the group size is
equal). After application of paired t test for comparisons of
compartments of each patient sample, average P values were
calculated to identify differentially expressed miRNAs between two
compartment groups. For multiple testing problems, a false discovery
rate was used [24]. In addition, fold change (FC) between the two
groups was calculated for each gene. DIANA miRPath v.2.0 was used
as a computational predictive model to calculate potentially targeted
genes and pathways using microT-CDS database (P value threshold
of .05, MicroT threshold of 0.8, false discovery rate correction, and
conservative stats were applied) [25]. Depicted pathways were derived
from the Kyoto Encyclopedia of Genes and Genomes (KEGG)
database [26].
Results
Using Affymetrix GeneChipR miRNA microarray, miRNA expres-
sion profiles were generated from six HCC samples that each had
been laser-microdissected into four subcompartments. After global
filtering (only miRNAs with an SD ≥ 1.5 across all samples were
used), a panel of 301 miRNAs was used to perform unsupervised
hierarchical clustering analysis (UCA) from 24 subcompartments.
UCA did not show a tissue-wise grouping of the four isolated
histologic sectors but rather showed a patient-dependent clustering of
subcompartments indicating a high interindividual variance of
miRNA expression patterns (Figure 1).
To increase robustness against the high global variation of miRNA
expression between the samples, a principal component analysis
(PCA) was calculated for each of the four subcompartments. Here,
the non-tumorous tissue compartments (TC and LC) show a closer
relationship, while liver tissue and tumor tissue remain widely
separated (Figure 2). Nevertheless, miRNA expression in TC and LC,
despite being morphologically similar, shows a clear separation in
the PCA.
To correct for the high interindividual variation observed in the
UCA, the supervised analysis was adapted to first calculate
intraindividual pairwise comparisons of subcompartments, while
the comparisons between different HCC samples were analyzed in a
second step. Pairwise comparisons of subcompartments showed
distinct patterns of expressed miRNAs for LC versus LP, TC versus
TP, LP versus TP, and LC versus TC (Table 3). Of note, LC and LP
show a number of differentially expressed miRNAs, supporting the
hypothesis that the degree of liver cirrhosis may significantly influence
the results of the miRNA expression analyses from patients with
HCC. This may be of special importance, when whole tissue sections
(comprising tumor tissue as well as TAT) are used for miRNA
profiling. For validation purposes, miRNAs differentially expressed
between LC and LP in this cohort were screened for in the expression
data from healthy non-cirrhotic livers deriving from one of our
previous works [27]. No dysregulation was found for these miRNAs
in healthy livers. Moreover, though LC and TC show identical
histomorphology and have a similar composition, there is a
pronounced difference in miRNA expression.
The results show a global down-regulation of miRNAs in TC
compared to LC, including miR-126, miR-125b, let-7 group, or
miR-26a. DIANA miRPath v2.0 enrichment analysis of predicted
miRNA target genes was used to identify pathways influenced by the
found miRNA profiles [25]. Interestingly, the TC profile was highly
enriched for several well-known oncogenic signaling pathways
Figure 1. Illustration of UCA of miRNA expression profiles generated from a total of 24 subcompartments. Heat map of profiles deriving
from microdissected FFPE tissue of six surgically resected HCC specimens (all HCV positive). The dendrogram is based on the
semiquantitative expression data after global filtering for miRNA probe sets with SD N 1.5. The color code on top of the illustration
represents the different patient samples. Subcompartments are displayed as color code below (tumor cells, yellow bars; liver cells, green
bars; tumor fibrinous capsule, red bars; liver fibrinous capsule, light purple bars). High expression in red and low expression in green.
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focal adhesion and extracellular matrix signaling (Pb 1E−10;
Table W1). Wnt and PI3K/Akt pathways with potentially affected
genes marked are shown in Figure S2.
The version of the Affymetrix miRNA Array (v2.0) used in the
present study allows screening for not only 1105 mature miRNAs but
also for their respective precursor (pre)-miRNA. The comparison of
TC and TP revealed several differentially expressed miRNAs, which
have only recently been added to the miRBase database (e.g., miR-
3201, miR-3128, and miR-3148). However, the majority of genes we
found dysregulated between compartments include previously
studied miRNAs. While five pre-miRNAs (pre-miR-1979, pre-
miR-520h, pre-miR-522, pre-miR-548i, and pre-miR-520g) were
found downregulated within the TC compartment as compared to
TP, all other comparisons of subcompartments did not feature
differentially expressed pre-miRNAs.
To simulate the comparison of whole sections of liver versus tumor
tissue, pairs of subcompartments (LP and LC vs TP and TC) were
pooled and consecutively compared for miRNA expression differ-
ences. As the individual compartments comprise different area
fractions within the tissue samples, every case was reviewed to
estimate percentages for each subcompartment within the wholetissue area. When the miRNA expression data were reanalyzed as
pooled data of TC and TP versus LC and LP, taking into account the
different percentages of tissue amounts, we found no differently
expressed miRNAs (Table S3).
Results from the microarray experiments were validated in a larger
independent cohort of patients with HCC (n= 20) using real-time
polymerase chain reaction (PCR) for four exemplary miRNAs (miR-
150, miR-126, and miR-146a). Differential regulation of miRNAs
discovered in the screening population was confirmed in the
validation cohort (Figure 3). The quantitative measurement of
expression correlated well with semiquantitative results from the
array experiments.
Furthermore, miRNA-ISH was performed as an additional step of
validation of two differentially expressed miRNAs (miR-150 and let-
7a). In line with the microarray data and real-time PCR results, both
miRNAs show markedly higher expression in the fibrous tissue
compartments and decreased expression in TC compared to LC
(Figure 4).
Twelve of 20 patients within the validation group received
transarterial chemoembolization (TACE). The samples from the
validation cohort were analyzed for impact of TACE therapy on the
expression of the validated miRNAs. There were no significant
Figure 2. PCA of miRNA expression profiles. Profiles derived from microdissected FFPE tissue of six surgically resected HCC specimens
(all HCV positive). The plot is based on the semiquantitative expression data after global filtering for miRNA probe sets with SD N 1.5. The
first principal component (x-axis) has the largest possible variance, and each succeeding component (y-axis, z-axis) has the highest
variance possible while being uncorrelated with the preceding components. Subcompartment color code: tumor cells, black; liver cells,
blue; liver fibrinous capsule, red; tumor fibrinous capsule, yellow.
Table 3. Supervised Analysis—Differentially Expressed miRNAs between Subcompartments
Liver Capsule versus Liver Parenchyma Tumor Capsule versus TP Liver Parenchyma versus TP Liver Capsule versus Tumor Capsule
miRNA FC P Value miRNA FC P Value miRNA FC P Value miRNA FC P Value
miR-19b −2.3 .03 miR-548c-3p 3.6 .02 miR-214 3.9 3.1E−6 miR-126 2.8 .002
let-7a 5.3 .03 miR-3201 −2.1 .03 miR-199a-5p 2.8 2.7E−4 miR-99a 2.0 .003
miR-16-2* −3.1 .04 p-miR-1979* −1.8 .03 miR-199a-3p 3.8 2.9E−4 miR-146a 4.6 .003
miR-150 4.2 .05 p-miR-520 h −1.9 .04 miR-199b-3p 3.4 4.9E−4 let-7 g 3.4 .004
miR-548a-3p −2.5 .05 miR-150 3.4 .04 miR-125a-5p 2.7 .002 miR-27a 2.8 .01
miR-425 1.7 .05 miR-3128 −2.3 .04 miR-342-3p 2.7 .003 miR-26a 2.5 .01
p-miR-522 −1.9 .04 miR-99b 1.9 .01 miR-150 3.7 .02
miR-335 −2.1 .04 miR-145 2.6 .01 miR-125b 2.8 .02
miR-548e 6.0 .05 let-7e 2.7 .02 let-7i 3.5 .02
let-7a 4.9 .05 miR-27a 2.6 .02 miR-100 2.2 .02
p-miR-548i 2.4 .05 miR-195 2.9 .02 miR-155 5.0 .02
miR-548a-3p 1.8 .05 miR-143 −2.9 .02 miR-199a-5p 3.0 .03
p-miR-520g −1.6 .05 miR-23a 2.8 .02 let-7c 2.8 .03
miR-3148 −2.6 .05 miR-150 −2.8 .03 miR-768-5p 2.0 .03
miR-146a 3.9 .03 miR-143 4.8 .03
miR-155 2.8 .04 miR-23a 3.3 .03
let-7a 3.1 .04
miR-195 3.8 .04
let-7f 3.4 .05
miR-199a-3p 5.7 .05
miR-342-3p 2.7 .05
MiRNA expression was compared case-wise for two compartments, respectively. Semiquantitative FC of miRNA expression and P value (paired t test) were calculated. miRNAs with FC ≥ 2 and P≤ .05 are
displayed. MiRNA that were chosen for validation experiments are printed in bold. *miR-1979 is rather a fragment of Y RNA and no miRNA. p-mir, precursor-miRNA.
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Figure 3. Validation by real-time RT-PCR for miRNAs miR-126, miR-146a, miR-150, and let-7a. Four representative miRNAs were selected
for validation by quantitative RT-PCR in an independent cohort of 20 HCV-positive HCC specimens. Samples were analyzed in triplicate
and ΔCt values were calculated using an endogenous control (U6). The analysis confirmed the dysregulation of selected miRNAs in the
different subcompartments with comparable results to the microarray analysis (Table 3). ΔCt values are depicted on the y-axis with
inverted scale. Values are displayed as box plots with mean, whiskers min to max (*Pb .05; **Pb .01).
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expression of miR-150, miR-126, miR-146a, or let-7a (Figure S3).
Discussion
HCC is an increasing burden in the world and is the second leading
cause of cancer-related mortality [4]. Most patients are diagnosed at
advanced stages, and thus, overall therapeutic options are limited and
the prognosis is poor [21]. Current treatment strategies for advanced
disease offer only limited efficacy [28,29]. MiRNAs are promising
candidates to act as future biomarkers in HCC as various studies
associated miRNA expression with early detection, prognosis, or
recurrence of HCC after resection [14,30,31]. Moreover, influencing
oncogenic or tumor-suppressive miRNAs may be a part of potent
future treatment strategies in HCC [32]. The development of
clinically reliable biomarkers or new drug targets is hampered by the
high versatility of the HCC phenotype.
Data published on miRNA expression in HCC are heterogeneous
and partly conflicting. Only few specific miRNAs were found
upregulated or downregulated in a consistent manner in more than
two studies [13]. The majority of patients with HCC suffer from
severe underlying liver disease. Despite efforts to correct for histologic
staging of liver fibrosis or etiology of liver disease, significant
interindividual differences in tissue gene expression likely remain.
This is also reflected by the UCA analysis in the current study.
Previous approaches compared miRNA expression of HCC tissue to
either TAT of the same patient or normal liver tissue deriving from
cohorts without liver disease. TAT is the preferred reference, as HCC
typically originates from severely altered fibrotic or cirrhotic liver
tissue. Still, even when TAT is used as reference, the comparisoninvolves not only HCC cells and liver cells but also includes the
tumor-surrounding cell compartment as well as fibrinous and
inflammatory tissue of the adjacent cirrhotic liver.
We hypothesized that the heterogeneity of data likely derives not
only from different molecular HCC pathomechanisms but may also
be attributable to variations in the tumor environment.
First, we found that the fibrotic tissue of the tumor adjacent non-
neoplastic liver expresses distinctively different miRNA patterns than
its neighboring liver tissue, including high semiquantitative expres-
sion differences for single miRNAs. The analysis of the combined
expression of LP and LC versus TP and TC showed that the
heterogeneity of pooled data probably prevented the detection of
differentially expressed miRNAs in this small sample size. Clearly, this
in silico approach of pooling of data has to be treated with caution as
the array analysis is only a semiquantitative method. Nevertheless, the
stage or distribution pattern of cirrhosis may induce a bias in studies
comparing miRNA expression from whole tissue sections of HCC
and adjacent non-tumorous liver tissue. This effect would be partly
compensated by well-matched patient cohorts or could average out
with increasing sample size. Indeed, the miRNA expression patterns
of microdissected HCC tissue compared to microdissected liver tissue
in our small cohort is most similar to the larger studies investigating
miRNA expression in HCC [13].
Second, this study is the first to describe the global miRNA
expression of HCC capsule tissue. The TC compartment demon-
strated an oncogenic phenotype. We observed that the fibrinous
tissue of the tumor capsule within and around the tumor has a
distinctively different miRNA expression pattern in comparison to
the fibrinous tissue within the tumor adjacent non-tumorous liver,
Figure 4.miRNA-ISH of miR-150 and let-7a. Representative microscopic pictures (40-fold magnification) of H&E staining and miRNA-ISH
on paraffin-embedded tissue sections (miRNA is stained blue). Left column (A, C, E): non-tumorous liver cells (LP) and surrounding fibrotic
tissue (LC); right column (B, D, F): non-tumorous liver (LP) with fibrotic tissue (LC) and HCC (TC) with surrounding tumor capsule (TC).
(A) H&E staining of LP and LC; (B) H&E staining of TP and TC; (C) miRNA-ISH for miR-150 demonstrating high expression in LC compared
to LP; (D) miRNA-ISH for miR-150 demonstrating high expression in LC and TC and higher expression in TP compared to LP; (E) miRNA-
ISH for let-7a demonstrating strongly increased expression in LC compared to LP; (F) miRNA-ISH for let-7a demonstrating high general
expression in the two fibrotic tissue compartments with stronger expression in LC versus TC and no difference between LP and TP.
Microscope: Nikon Eclipse E1000. Camera: Nikon DS-Ri 1.
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feature comparable composition of cell types. The differentially
expressed genes compared to LC included known tumor-suppressive
miRNAs such as miR-126, miR-99/100, miR-26a, or let-7 group
[33–37]. The miRNAs downregulated in TC to some extent resemble
those also downregulated in the corresponding HCC cell compart-
ment (e.g., miR-146a, miR-27a, miR-155, or miR-342-3p).
However, we found several miRNAs dysregulated exclusively in the
TC compartment, which have been evaluated as promising
prognostic biomarkers or implicated in HCC pathogenesis
(miR-126, miR-99a, miR-100, miR-26a, and miR-125b)
[32,38–42]. Moreover, well-known oncogenic pathways were
found highly enriched in the MiRPath analysis supporting thesuggestion of a premalignant phenotype of the TC. Laser
microdissection on a cellular level was used to ensure that results of
the TC compartment truly represent measurements from the
fibrinous tumor capsule and not only of the leading tumor edge.
Furthermore, the miRNA-ISH technique was used to confirm and
visualize miRNA dysregulation by the respective compartment,
although it has to be taken into the account that the comparability to
quantitative methods such as quantitative PCR is limited.
Prognostic biomarkers and novel therapeutic concepts in HCC are
urgently needed. The tumor microenvironment likely plays a decisive
role in HCC pathogenesis. Indeed, patterns of miRNAs expressed
within the tumor adjacent liver tissue of patients with HCC are
associated with tumor recurrence after surgical resection [43,44].
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tumors for systemic chemotherapies [45,46]. Therefore, the TC may
be a potential drug target to improve outcome in HCC. Therapeutic
miRNA delivery has been successfully applied to suppress tumori-
genesis in a murine liver cancer model [32]. Consequently, specific
tissue compartments might be of high relevance in future therapeutic
studies aiming to modulate miRNAs in HCC. Thus, targeting
strategies for the different cell types involved in the tumorigenesis may
be quite different. With our analysis, we provide additional insight
into potential oncogenic and tumor-suppressive mechanisms within
the tumor-surrounding tissue compartments and offer possible
vantage points for new treatment approaches.
Several limitations of our study have to be acknowledged. Our
analysis is limited by a rather small case number, as we aimed to match
included patients meticulously for any confounding factors, such as
tumor stage, etiology of liver disease, or extent of fibrosis. In addition,
we focused on early-stage HCC (BCLC stage 0/A), so the possibility to
translate our findings to more advanced stages of HCC is clearly
limited. Nevertheless, the validity of our data could be demonstrated
by application of complimentarymethods of miRNA quantification in
an independent patient cohort. Through microscopic visualization
during and after microdissection a cross-contamination between tissue
compartments can be effectively excluded. However, there is still a
mixture of cell types within the isolated compartments, e.g., the tumor
capsule compartment, among others, comprises fibroblasts, lympho-
cytes, and granulocytes. Analysis of miRNA signatures from single-cell
fractions within our HCC compartments may address this issue in
future studies. Furthermore, the percentage of female patients with
66% in the screening cohort is high compared to the typical
population of patients with HCC [47]. Moreover, in this study, only
HCV-associated HCC was investigated. It would be valuable to study
the miRNA expression of the tumor microenvironment in HCC
patients with other etiologies of underlying liver disease.
In conclusion, our data support the hypothesis that the heterogeneity
of published data on miRNA expression in HCC may, in part, be
attributable to variations of co-analyzed fibrotic tissue in the tumor and
in controls. The use of TAT as control is of high importance, but analyses
may still be subject of significant bias through variations in quantity and
quality of fibrinous or cirrhotic tissue within the control tissue. The
tumor capsule demonstrates a tumor-like phenotype with down-
regulation of well-known tumor-suppressive miRNAs. Several miRNAs
that are proposed to be HCC specific might indeed be rather associated
to the tumor capsule. The finding that miRNA dysregulation varies
within tumor compartments can be important for the development of
future treatment strategies in HCC.
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